NCT03916419

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Completed Phase 2 Last updated 12 November 2025

What this trial tests

Phase 2 trial testing ViewRay MR-Linear Accelerator in Stage IIB Non-Small Cell Lung Cancer in 26 participants. Completed in 28 September 2025.

Timeline

20 June 2019

Primary endpoint
28 September 2025

28 September 2025

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	20 June 2019
Primary completion	28 September 2025
Estimated completion	28 September 2025
Sites	1 location across United States

Drugs / interventions tested

• ViewRay MR-Linear Accelerator
• Radiation therapy — full drug profile →
• Paclitaxel — full drug profile →
• Carboplatin AUC
• Durvalumab — full drug profile →

Conditions studied

• Stage IIB Non-Small Cell Lung Cancer — all drugs for Stage IIB Non-Small Cell Lung Cancer →
• Stage IIIA Non-small Cell Lung Cancer — all drugs for Stage IIIA Non-small Cell Lung Cancer →
• Stage IIIB Non-small Cell Lung Cancer — all drugs for Stage IIIB Non-small Cell Lung Cancer →
• Stage IIIC Non-Small Cell Lung Cancer — all drugs for Stage IIIC Non-Small Cell Lung Cancer →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Stage IIB Non-Small Cell Lung Cancer or Stage IIIA Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small cell lung cancer (NSCLC), this prospective, single-arm Phase II clinical trial with safety lead-in will test the feasibility and outcomes of this approach.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Radiotherapy combined with immunotherapy: the dawn of cancer treatment.
   Zhang Z, Liu X, Chen D, Yu J. · · 2022 · cited 463× · PMID 35906199 · DOI 10.1038/s41392-022-01102-y
2. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
   Pellini B, Chaudhuri AA. · · 2022 · cited 143× · PMID 34985936 · DOI 10.1200/jco.21.01929
3. Advances in the Molecular Landscape of Lung Cancer Brain Metastasis.
   Souza VGP, de Araújo RP, Santesso MR, Seneda AL, et al · · 2023 · cited 32× · PMID 36765679 · DOI 10.3390/cancers15030722
4. Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer.
   Crockett CB, Samson P, Chuter R, Dubec M, et al · · 2021 · cited 22× · PMID 33777759 · DOI 10.3389/fonc.2021.617681
5. MR-LINAC, a New Partner in Radiation Oncology: Current Landscape.
   Ocanto A, Torres L, Montijano M, Rincón D, et al · · 2024 · cited 18× · PMID 38254760 · DOI 10.3390/cancers16020270
6. MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients.
   Eze C, Lombardo E, Nierer L, Xiong Y, et al · · 2022 · cited 18× · PMID 35209922 · DOI 10.1186/s13014-022-02011-8
7. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
   Chuong MD, Clark MA, Henke LE, Kishan AU, et al · · 2023 · cited 16× · PMID 36466748 · DOI 10.1016/j.ctro.2022.11.013
8. Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.
   Regnery S, de Colle C, Eze C, Corradini S, et al · · 2023 · cited 12× · PMID 37143154 · DOI 10.1186/s13014-023-02258-9